GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Tax Expense

Athenex (Athenex) Tax Expense : $0.3 Mil (TTM As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Athenex Tax Expense?

Athenex's tax expense for the months ended in Dec. 2022 was $-0.3 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2022 was $0.3 Mil.


Athenex Tax Expense Historical Data

The historical data trend for Athenex's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Tax Expense Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tax Expense
Get a 7-Day Free Trial 0.10 0.93 4.09 -10.60 0.35

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 -0.02 0.60 -0.26

Athenex Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athenex  (OTCPK:ATNXQ) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Athenex Tax Expense Related Terms

Thank you for viewing the detailed overview of Athenex's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Athenex (Athenex) Business Description

Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Executives
Jinn Wu director 107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam director, officer: CEO and Chairman of the Board
Joe Annoni officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook officer: See Remarks C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang officer: Pres Cell Therapy, VP Corp Dev C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan director, officer: EVP, Chief Medical Officer C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski officer: Chief Scientific Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams officer: Interim Chief Acct Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell director 3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo officer: President, China 3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok director C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze officer: Chief Financial Officer C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis director C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203